BioXcel Reports Positive Phase 3 At-Home Agitation Data
NEW HAVEN, Conn. | May 28, 2026 BioXcel Therapeutics presented new positive data from its Phase 3 SERENITY At-Home...
bipolar disorder
Advertisement
Teva Uncovers Widespread Underdiagnosis of Tardive Dyskinesia in Young Patients
PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026 Teva Pharmaceuticals has announced new findings from its ongoing IMPACT-TD...
BioXcel IGALMI sNDA Accepted by FDA for At-Home Use
NEW HAVEN, Conn., USA — April 1, 2026 BioXcel Therapeutics, Inc. announced that the U.S. Food and Drug Administration...
Lupin Debuts CGT-Exclusive Risperidone LAI in U.S. Market
Dateline: November 14, 2025 — Mumbai, India / Baltimore, MarylandLupin has launched its Risperidone Long-Acting Injectable (LAI) in the...
Advertisement
